Schedule 13D ownership disclosure
REVIVA PHARMACEUTCLS HLDGS I
Common Stock, $0.0001 par value · CUSIP: 76152G100
Event date: 2025-06-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vedanta Associates, L.P.Reported CIK 0001502222
Shares: 3,408,401.00 · Class: 4.8%
- VEDANTA PARTNERS, LLCReported CIK 0001502216
Shares: 5,367,069.00 · Class: 7.5%
- Parag SaxenaReported CIK 0001015823
Shares: 6,259,806.00 · Class: 8.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001641172-25-017411
- Form type
- SCHEDULE 13D/A
- Filer
- REVIVA PHARMACEUTICALS HOLDINGS, INC.
- CIK
- CIK 1742927
- Filed
- Jul 01, 2025
- Reporting period
- Jun 27, 2025
- Description
- Schedule 13D beneficial ownership